Fabentech reinforces its Board to drive global expansion
Appointment of Dario Eklund and Tommi Kainu to the Supervisory board
Strengthened governance to support commercial acceleration
Lyon, France, July 9th, 2025 – Fabentech, a biopharmaceutical company specialized in immunotherapies to combat both emerging infectious diseases with pandemic potential and biological agents that may be used in acts of terrorism, crime, or warfare, strengthens its supervisory Board with the appointment of Dario Eklund and Tommi Kainu, as Independent Board Members.
These appointments further reinforce the company’s governance as it enters its commercial phase and positions for international expansion.
Following the successful clinical development of its lead product, Fabentech has secured its first European customers. With a growing pipeline, the company is now poised to leverage its industrial capabilities and commercial potential to consolidate its leadership in biodefense and pandemic preparedness.
Dario Eklund, currently CEO of Santhera Pharmaceuticals, brings more than 30 years of global biopharma experience, having held senior leadership roles at Vifor Pharma and Organogenesis. His expertise spans commercialization, licensing, and international expansion in rare diseases and specialty medicines.
Fabentech has all the ingredients of a high-impact, purpose-driven company
It’s a privilege to support its mission to deliver life-saving treatments and build a global biodefense platform
said Dario Eklund
Dr. Tommi Kainu, Executive Chairman of GlyProVac and former Chief Business Officer of Bavarian Nordic, brings extensive experience from the biotech and vaccine industries, combined with nearly two decades at the Boston Consulting Group. His expertise in strategic transformation, infectious diseases, and public-private partnerships will be instrumental in supporting Fabentech’s next growth phase.
From product development to public health readiness, Fabentech’s work is both timely and essential,
I’m excited to join a company so well-positioned to make a global difference.
said Dr. Tommi Kainu
We are delighted to welcome Dario and Tommi to the Supervisory Board,Their international expertise will complement the strong scientific and strategic foundation we’ve built to accelerate Fabentech’s global growth and impact in health security.
said Philippe Archinard, Institut Merieux’s Representative and Chairman of the Board.
In a world increasingly exposed to biological threats—from global instability to climate change and the risk of deliberate attacks—Fabentech’s mission has never been more relevant,
With Dario and Tommi joining the Board, we gain the strategic insight needed to navigate international markets and deliver on our commitment to protect populations through broad-spectrum therapeutics
added Sébastien Iva, CEO of Fabentech
These appointments further strengthen Fabentech’s Supervisory Board, which now includes:
Institut Mérieux, represented by Philippe Archinard, Chairman of the Supervisory Board
Definvest / Bpifrance Investissement, represented by Marielle Mailhes
Trail Solutions Patrimoine, represented by Guillaume Hemmerlé
AURIGA IV Bioseeds fund, represented by Franck Lescure
UI Investissement, represented by Camille Curtil
Bertrand Lépine, Founder of Fabentech
Together, the Supervisory Board brings strategic, financial, and development expertise to guide Fabentech as it scales its role in European health preparedness and expands its footprint in the global therapeutic landscape.
About FABENTECH
Founded in 2009 and based in Lyon, Fabentech is a biopharmaceutical company specialized in the development, production and marketing of polyclonal antibodies for responding to emergency situations.
Specializing in biothreats and working in close partnership with the European Authorities, the company’s goal is to build a domestic and European shield against the biological threats that are the greatest risk to public health by producing and marketing targeted antidotes to be stocked preventively.
The polyclonal antibody technology used by Fabentech holds great potential for the development of antidotes against bioterrorist attacks and treatments for numerous infectious diseases. Fabentech has 50 staff and is financially supported by leading investors such as Definvest and Institut Mérieux.
For more information : www.fabentech.fr
Contact
Sébastien IVA
Président du Directoire
Chief Executive Officer
24, rue Jean Baldassini
69007 LYON- France
+33 4 37 70 67 67
